Tumor volumes in the combination group were smaller than those in either monotherapy group, corroborating that STING pathway activation by ADU-S100 enhances the antitumor efficacy of doxorubicin in vivo (Supplementary Figure 3). The gene discussed is STING1; the disease is neoplasm.